Adrenomedullin and endothelial barrier function

Thrombosis and Haemostasis

Volumn 98, Issue 5, 2007, Pages 944-951

  Temmesfeld Wollbrück, Bettina ^a   Hocke, Andreas C ^a   Suttorp, Norbert ^a   Hippenstiel, Stefan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adrenomedullin; Endothelium; Inflammation; Permeability; Sepsis

Indexed keywords

ADRENOMEDULLIN; CALCITONIN RECEPTOR LIKE RECEPTOR; CYCLIC AMP; PROCOAGULANT; PROTEIN ZO1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR ACTIVITY MODIFYING PROTEIN 3;

ACTIN MYOSIN INTERACTION; ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; EDEMA; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; VASCULAR ENDOTHELIUM;

ADRENOMEDULLIN; CARDIOTONIC AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; PERMEABILITY; SEPSIS;

EID: 36049023200     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-02-0128     Document Type: Article

References (151)

1. Bazzoni G. Endothelial tight junctions: permeable barriers of the vessel wall. Thromb Haemost 2006; 95: 36-42.
2. Lush CW, Kvietys PR. Microvascular dysfunction in sepsis. Microcirculation 2000; 7: 83-101.
3. Mehta D, Malik AB. Signaling mechanisms regulating endothelial permeability. Physiol Rev 2006; 86: 279-367.
4. Nieuw Amerongen GP, van Hinsbergh VW. Targets for pharmacological intervention of endothelial hyperpermeability and barrier function. Vascul Pharmacol 2002; 39: 257-272.
5. Stevens T, Garcia JG, Shasby DM, et al. Mechanisms regulating endothelial cell barrier function. Am J Physiol Lung Cell Mol Physiol 2000; 279: L419-L422.
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
7. Volk T, Kox WJ. Endothelium function in sepsis. Inflamm Res 2000; 49: 185-198.
8. Hippenstiel S, Suttorp, N. Interaction of pathogens with the endothelium. Thromb Haemost 2003; 89: 18-24.
9. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005; 21: 177-196.
10. Suratt BT, Parsons PE. Mechanisms of acute lung injury/acute respiratory distress syndrome. Clin Chest Med 2006; 27: 579-589.
11. Orfanos SE, Mavrommati I, Korovesi I, et al. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med 2004; 30: 1702-1714.
12. Marx G. Fluid therapy in sepsis with capillary leakage. Eur J Anaesthesiol 2003; 20: 429-442.
13. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200: 639-646.
14. Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 2000; 20: 131-147.
15. van Hinsbergh WM. Endothelial permeability for macromolecules. Mechanistic aspects of pathophysiological modulation. Arterioscler Thromb Vasc Biol 1997; 17: 1018-1023.
16. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol Rev 2004; 84: 869-901.
17. Hirase T, Staddon JM, Saitou M, et al. Occludin as a possible determinant of tight junction permeability in endothelial cells. J Cell Sci 1997; 110: 1603-1613.
18. Orlova VV, Economopoulou M, Lupu F, et al. Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts. J Exp Med 2006; 203: 2703-2714.
19. van Hinsbergh VW, van Amerongen GP. Intracellular signalling involved in modulating human endothelial barrier function. J Anat 2002; 200: 549-560.
20. Yuan SY. Protein kinase signaling in the modulation of microvascular permeability. Vascul Pharmacol 2002; 39: 213-223.
21. Bogatcheva NV, Garcia JG, Verin AD. Molecular mechanisms of thrombin-induced endothelial cell permeability. Biochemistry (Mosc) 2002; 67: 75-84.
22. Nieuw Amerongen GP, van Hinsbergh VW. Cytoskeletal effects of rho-like small guanine nucleotide-binding proteins in the vascular system. Arterioscler Thromb Vasc Biol 2001; 21: 300-311.
23. Garcia JG, Verin AD, Schaphorst KL. Regulation of thrombin-mediated endothelial cell contraction and permeability. Semin Thromb Hemost 1996; 22: 309-315.
24. Miller FN, Sims DE. Contractile elements in the regulation of macromolecular permeability. Fed Proc 1986; 45: 84-88.
25. Bogatcheva NV, Adyshev D, Mambetsariev B, et al. Involvement of microtubules, p38 and Rho kinases pathway in 2-methoxyestradiol-induced lung vascular barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 2006; 292: L487-499.
26. Birukova AA, Birukov KG, Adyshev D, et al. Involvement of microtabules and Rho pathway in TGF-betal-induced lung vascular barrier dysfunction. J Cell Physiol 2005; 204: 934-947.
27. Birukova AA, Birukov KG, Gorshkov B, et al. MAP kinases in lung endothelial permeability induced by microtubule disassembly. Am J Physiol Lung Cell Mol Physiol 2005; 289: L75-L84.
28. Birukova AA, Birukov KG, Gmurova K, et al. Novel role of microtubules in thrombin-induced endothelial barrier dysfunction. FASEB J 2004; 18: 1879-1990.
29. Birukova AA, Smurova K, Birukov KG, et al. Microtubule disassembly induces cytoskeletal remodeling and lung vascular barrier dysfunction: role of Rho-dependent mechanisms. J Cell Physiol 2004; 201: 55-70.
30. Petrache I, Birukova A, Ramirez SI, et al. The role of the microtubules in tumor necrosis factor-alpha-induced endothelial cell permeability. Am J Respir Cell Mol Biol 2003; 28: 574-581.
31. Katz J, Sambandam V, Wu JH, et al. Characterization of Porphyromonas gingivalis-induced degradation of epithelial cell junctional complexes. Infect Immun 2000; 68: 1441-1449.
32. Katz J, Yang QB, Zhang P, et al. Hydrolysis of epithelial junctional proteins by Porphyromonas gingivalis gingipains. Infect Immun 2002; 70: 2512-2518.
33. Carden D, Xiao F, Moak C, et al. Neutrophil elastase promotes lung microvascular injury and proteolysis of endothelial cadherins. Am J Physiol 1998; 275: H385-H392.
34. Suttorp, N, Nolte A, Wilke A, et al. Human neutrophil elastase increases permeability of cultured pulmonary endothelial cell monolayers. Int J Microcirc Clin Exp 1993; 13: 187-203.
35. Brell B, Hippenstiel S, David I, et al. Adrenomedullin treatment abolishes ileal mucosal hypoperfusion induced by Staphylococcus aureus alpha-toxin-an intravital microscopic study on an isolated rat ileum. Crit Care Med 2005; 33: 2810-2816.
36. Seeger W, Birkemeyer RG, Ermert L, et al. Staphylococcal alpha-toxin-induced vascular leakage in isolated perfused rabbit lungs. Lab Invest 1990; 63: 341-349.
37. Suttorp N, Hessz T, Fuchs T, et al. Effects of bacterial toxins and calcium-ionophores on endothelial permeability in vitro. Prog Clin Biol Res 1989; 308: 127-131.
38. Suttorp N, Hessz T, Seeger W, et al. Bacterial exotoxins and endothelial permeability for water and albumin in vitro. Am J Physiol 1988; 255: C368-C376.
39. Hippenstiel S, Witzenrath M, Schmeck B, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002; 91: 618-625.
40. Suttorp N, Hippenstiel S, Fuhrmann M, et al. Role of nitric oxide and phosphodiesterase isoenzyme II for reduction of endothelial hyperpermeability. Am J Physiol 1996; 270: C778-C785.
41. Seeger W, Walter H, Neuhof H, et al. Escherichia coli hemolysin causes thromboxane-mediated hypertension and vascular leakage in rabbit lungs. Prog Clin Biol Res 1989; 308: 67-72.
42. Seeger W, Hansen T, Rossig R, et al. Hydrogen peroxide-induced increase in lung endothelial and epithelial permeability-effect of adenylate cyclase stimulation and phosphodiesterase inhibition. Microvasc Res 1995; 50: 1-17.
43. Suttorp N, Weber U, Welsch T, et al. Role of phosphodiesterases in the regulation of endothelial permeability in vitro. J Clin Invest 1993; 91: 1421-1428.
44. Seybold J, Thomas D, Witzenrath M, et al. Tumor necrosis factor-alpha-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 2005; 105: 3569-3576.
45. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993; 192: 553-560.
46. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54: 233-246.
47. Lopez J, Martinez A. Cell and molecular biology of the multifunctional peptide, adrenomedullin. Int Rev Cytol 2002; 221: 1-92.
48. Beltowski J, Jamroz A. Adrenomedullin - what do we know 10 years since its discovery? Pol J Pharmacol 2004; 56: 5-27.
49. Jougasaki M, Burnett JC, Jr. Adrenomedullin: potential in physiology and pathophysiology. Life Sci 2000; 66: 855-872.
50. Shimosawa T, Fujita T. Adrenomedullin and its related peptide. Endocr J 2005; 52: 1-10.
51. Kitamura K, Kangawa K, Ishiyama Y, et al. Identification and hypotensive activity of proadrenomedullin N-terminal 20 peptide (PAMP). FEB S Lett 1994; 351: 35-37.
52. Kitamura K, Kangawa K, Eto T. Adrenomedullin and PAMP: discovery, structures, and cardiovascular functions. Microsc Res Tech 2002; 57: 3-13.
53. Martinez A, Hodge DL, Garayoa M, et al. Alternative splicing of the proadrenomedullin gene results in differential expression of gene products. J Mol Endocrinol 2001; 27: 31-41.
54. Samson WK. Proadrenomedullin-derived peptides. Front Neuroendocrinol 1998; 19: 100-127.
55. Struck J, Tao C, Morgenthaler NG, et al. Identification of an Adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 2004; 25: 1369-1372.
56. Watanabe TX, Itahara Y, Inui T, et al. Vasopressor activities of N-terminal fragments of adrenomedullin in anesthetized rat. Biochem Biophys Res Commun 1996; 219: 59-63.
57. Gumusel B, Hao Q, Hyman AL, et al. Analysis of responses to adrenomedullin-(13-52) in the pulmonary vascular bed of rats. Am J Physiol 1998; 274: H1255-H1263.
58. Eguchi S, Hirata Y, Iwasaki H, et al. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. Endocrinology 1994; 135: 2454-2458.
59. Shimosawa T, Kanozawa K, Nagasawa R, et al. Adrenomedullin amidation enzyme activities in hypertensive patients. Hypertens Res 2000; 23: 167-171.
60. Hirayama N, Kitamura K, Imamura T, et al. Secretion and clearance of the mature form of adrenomedullin in humans. Life Sci 1999; 64: 2505-2509.
61. Kitamura K, Kato J, Kawamoto M, et al. The intermediate form of glycine-extended adrenomedullin is the major circulating molecular form in human plasma. Biochem Biophys Res Commun 1998; 244: 551-555.
62. Isumi Y, Shoji H, Sugo S, et al. Regulation of adrenomedullin production in rat endothelial cells. Endocrinology 1998; 139: 838-846.
63. Tomoda Y, Isumi Y, Katafuchi T, et al. Regulation of adrenomedullin secretion from cultured cells. Peptides 2001; 22: 1783-1794.
64. Zaks-Zilberman M, Salkowski CA, Elsasser T, et al. Induction of adrenomedullin mRNA and protein by lipopolysaccharide and paclitaxel (Taxol) in murine macrophages. Infect Immun 1998; 66: 4669-4675.
65. Zhou M, Chaudry IH, Wang P. Adrenomedullin is upregulated in the heart and aorta during the early and late stages of sepsis. Biochim Biophys Acta 1999; 1453: 273-283.
66. Zhou M, Chaudry IH, Wang P. The small intestine is an important source of adrenomedullin release during polymicrobial sepsis. Am J Phygiol Regul Integr Comp Physiol 2001; 281: R654-R660.
67. Albertin G, Ruggero M, Guidolin D, et al. Gene silencing of human RAMP2 mediated by short-interfering RNA. Int J Mol Med 2006; 18: 531-535.
68. Buhlmann N, Leuthauser K, Muff R, et al. A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1. Endocrinology 1999; 140: 2883-2890.
69. Conner AC, Simms J, Hay DL, et al. Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin. Biochem Soc Trans 2004; 32: 843-846.
70. Dackor RT, Fritz-Six K, Dunworth WP, et al. Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the calcitonin receptor-like receptor gene. Mol Cell Biol 2006; 26: 2511-2518.
71. Dschietzig T, Azad HA, Asswad L, et al. The adrenomedullin receptor acts as clearance receptor in pulmonary circulation. Biochem Biophys Res Commun 2002; 294: 315-318.
72. Gibbons C, Dackor R, Dunworth W, et al. Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling. Mol Endocrinol 2006; 21: 783-796.
73. Grant AD, Tam CW, Lazar Z, et al. The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature. Br J Pharmacol 2004; 142: 1091-1098.
74. Hay DL, Poyner DR, Smith DM. Desensitisation of adrenomedullin and CGRP receptors. Regul Pept 2003; 112: 139-145.
75. Kamitani S, Asakawa M, Shimekake Y, et al. The RAMP2/CRLR complex is a functional adrenomedullin receptor in human endothelial and vascular smooth muscle cells. FEBS Lett 1999; 448: 111-114.
76. Nikitenko LL, Blucher N, Fox SB, et al. Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. J Cell Sci 2006; 119: 910-922.
77. Smith DM, Coppock HA, Withers DJ, et al. Adrenomedullin: receptor and signal transduction. Biochem Soc Trans 2002; 30: 432-437.
78. Tam CW, Husmann K, Clark NC, et al. Enhanced vascular responses to adrenomedullin in mice over-expressing receptor-activity-modifying protein 2. Circ Res 2006; 98: 262-270.
79. Barker S, Kapas S, Corder R, et al. Adrenomedullin acts via stimulation of cyclic AMP and not via calcium signalling in vascular cells in culture. J Hum Hypertens 1996; 10: 421-423.
80. Kuwasako K, Cao YN, Nagoshi Y, et al. Adrenomedullin receptors: pharmacological features and possible pathophysiological roles. Peptides 2004; 25: 2003-2012.
81. Shimekake Y, Nagata K, Ohta S, et al. Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation and Ca2+ mobilization, in bovine aortic endothelial cells. J Biol Chem 1995; 270: 4412-4417.
82. Yurugi-Kobayashi T, Itoh H, Schroeder T, et al. Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol 2006; 26: 1977-1984.
83. Dong F, Taylor MM, Samson WY, et al. Intermedin (adrenomedullin-2) enhances cardiac contractile function via a protein kinase C- and protein kinase A-dependent pathway in murine ventricular myocytes. J Appl Physiol 2006; 101: 778-784.
84. Parameswaran N, Hall CS, McCabe LR, etal. Adrenomedullin increases AP-1 expression in rat mesangial cells via activation of protein kinase-A and p38 MAPK. Cell Physiol Biochem 2003; 13: 367-374.
85. Xu Y, Krukoff TL. Adrenomedullin in the rostral ventrolateral medulla inhibits baroreflex control of heart rate: a role for protein kinase A. Br J Pharmacol 2006; 148: 70-77.
86. Liu J, Shimosawa T, Matsui H, et al. Adrenomedullin inhibits angiotensin II-induced oxidative stress via Csk-mediated inhibition of Src activity. Am J Physiol Heart Circ Physiol 2007; 292: H1714-1721.
87. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003; 17: 1937-1939.
88. Miyashita K, Itoh H, Sawada N, et al. Adrenomedullin provokes endothelial Akt activation and promotes vascular regeneration both in vitro and in vivo. FEBS Lett 2003; 544: 86-92.
89. Nishimatsu H, Suzuki E, Nagata D, et al. Adrenomedullin induces endothelium-dependent vasorelaxation via the phosphatidylinositol 3-kinase/Akt-dependent pathway in rat aorta. Circ Res 2001; 89: 63-70.
90. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation 2004; 109: 242-248.
91. Parameswaran N, Nambi P, Hall CS, et al. Adrenomedullin decreases extracellular signal-regulated kinase activity through an increase in protein phosphatase-2A activity in mesangial cells. Eur J Pharmacol 2000; 388: 133-138.
92. Garcia MA, Martin-Santamaria S, Pascual-Teresa B, et al. Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets 2006; 10: 303-317.
93. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000; 21: 138-167.
94. Kato J, Tsuruda T, Kita T, et al. Adrenomedullin: a protective factor for blood vessels. Arterioscler Thromb Vasc Biol 2005; 25: 2480-2487.
95. Nikitenko LL, Smith DM, Hague S, et al. Adrenomedullin and the microvasculature. Trends Pharmacol Sci 2002; 23: 101-103.
96. Nikitenko LL, Fox SB, Kehoe S, et al. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006; 94: 1-7.
97. Samson WK. Adrenomedullin and the control of fluid and electrolyte homeostasis. Annu Rev Physiol 1999; 61: 363-389.
98. Vijay P. Adrenomedullin in the treatment of pulmonary hypertension. Heart 2000; 84: 575-576.
99. Wang P. Adrenomedullin in sepsis and septic shock. Shock 1998; 10: 383-384.
100. Wang P. Andrenomedullin and cardiovascular responses in sepsis. Peptides 2001; 22: 1835-1840.
101. Allaker RP, Grosvenor PW, McAnerney DC, et al. Mechanisms of adrenomedullin antimicrobial action. Peptides 2005; 27: 661-666.
102. Zudaire E, Portal-Nunez S, Cuttitta F. The central role of adrenomedullin in host defense. J Leukoc Biol 2006; 80: 237-244.
103. Hirata Y, Mitaka C, Sato K, et al. Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 1996; 81: 1449-1453.
104. Nishio K, Akai Y, Murao Y, et al. Increased plasma concentrations of adrenomedullin correlate with relaxation of vascular tone in patients with septic shock. Crit Care Med 1997; 25: 953-957.
105. Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 1999; 160: 132-136.
106. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397], Crit Care 2006; 10: R96.
107. Wang P, Zhou M, Ba ZF, et al. Up-regulation of a novel potent vasodilatory peptide adrenomedullin during polymicrobial sepsis. Shock 1998; 10: 118-122.
108. Li YY, Wong LY, Cheung BM, et al. Differential induction of adrenomedullin, interleukins and tumour necrosis factor-alpha by lipopolysaccharide in rat tissues in vivo. Clin Exp Pharmacol Physiol 2005; 32: 1110-1118.
109. Cheung BM, Hwang IS, Li CY, et al. Increased adrenomedullin expression in lungs in endotoxaemia. J Endocrinol 2004; 181: 339-345.
110. Matsui E, Kitamura K, Yoshida M, et al. Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat model of endotoxin shock. Hypertens Res 2001; 24: 543-549.
111. Agotreta J, Zulueta JJ, Montuenga LM, et al. Adrenomedullin expression in a rat model of acute lung injury induced by hypoxia and LPS. Am J Physiol Lung Cell Mol Physiol 2005; 288: L536-L545.
112. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci U S A 2001; 98: 615-619.
113. Czyzyk TA, Ning Y, Hsu MS, et al. Deletion of peptide amidation enzymatic activity leads to edema and embryonic lethality in the mouse. Dev Biol 2005; 287: 301-313.
114. Brell B, Temmesfeld-Wollbruck B, Altzschner I, et al. Adrenomedullin reduces Staphylococcus aureus alpha-toxin-induced rat ileum microcirculatory damage. Crit Care Med 2005; 33: 819-826.
115. Hocke AC, Temmesfeld-Wollbrueck B, Schmeck B, et al. Perturbation of endothelial junction proteins by Staphylococcus aureus alpha-toxin: inhibition of endothelial gap formation by adrenomedullin. Histochem Cell Biol 2006; 126: 305-316.
116. Kis B, Deli MA, Kobayashi H, et al. Adrenomedullin regulates blood-brain barrier ftinctions in vitro. Neuroreport 2001; 12: 4139-4142.
117. Kis B, Snipes JA, Deli MA, et al. Chronic adrenomedullin treatment improves blood-brain barrier function but has no effects on expression of tight junction proteins. Acta Neurochir Suppl 2003; 86: 565-568.
118. Ohbayashi H, Suito H, Yoshida N, et al. Adrenomedullin inhibits ovalbumin-induced bronchoconstriction and airway microvascular leakage in guinea-pigs. Eur Respir J 1999; 14: 1076-1081.
119. Tam C, Brain SD. The assessment of vasoactive properties of CGRP and adrenomedullin in the microvasculature: a study using in vivo and in vitro assays in the mouse. J Mol Neurosci 2004; 22: 117-124.
120. Honda M, Nakagawa S, Hayashi K, et al. Adrenomedullin improves the blood-brain barrier function through the expression of claudin-5. Cell Mol Neurobiol 2006; 26: 109-118.
121. Suttorp N, Ehrciser P, Hippenstiel S, et al. Hyperpermeability of pulmonary endothelial monolayer: protective role of phosphodiesterase isoenzymes 3 and 4. Lung 1996; 174: 181-194.
122. Szokodi I, Kinnunen P, Tavi P, et al. Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 1998; 97: 1062-1070.
123. Bos JL. Epac proteins: multi-purpose cAMP targets. Trends Biochem Sci 2006; 31: 680-686.
124. Cullere X, Shaw SK, Andersson L, et al. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 2005; 105: 1950-1955.
125. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AW potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol 2005; 25: 136-146.
126. Akiyama S, Hatanaka Y, Hobara N, et al. Effect of adrenomedullin on adrenergic vasoconstriction in mesenteric resistance arteries of the rat. J Pharmacol Sci 2005; 99: 264-271.
127. Shindo T, Kurihara H, Maemura K, et al. Hypotension and resistance to lipopolysaccharide-induced shock in transgenic mice overexpressing adrenomedullin in their vasculature. Circulation 2000; 101: 2309-2316.
128. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001; 104: 1964-1971.
129. Shirai M, Shimouchi A, Ikeda S, et al. Vasodilator effects of adrenomedullin on small pulmonary arteries and veins in anaesthetized cats. Br J Pharmacol 1997; 121: 679-686.
130. Ueda K, Teragawa H, Kimura M, et al. Adrenomedullin causes coronary vasodilation in humans: effects of inhibition of nitric oxide synthesis. J Cardiovasc Pharmacol 2005; 46: 534-539.
131. Temmesfeld-Wollbruck B, Brell B, David I, et al. Adrenomedullin reduces vascular hyperpermeability and improves survival in rat septic shock. Intensive Care Med 2007; 33: 703-710.
132. Gonzalez-Rey E, Chorny A, Varela N, et al. Urocortin and adrenomedullin prevent lethal endotoxemia by down-regulating the inflammatory response. Am J Pathol 2006; 168: 1921-1930.
133. Yang S, Zhou M, Chaudry IH, et al. Novel approach to prevent the transition from the hyperdynamic phase to the hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1. Ann Surg 2002; 236: 625-633.
134. Yang S, Zhou M, Fowler DE, et al. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines. Crit Care Med 2002; 30: 2729-2735.
135. Cui X, Wu R, Zhou M, et al. Adrenomedullin and its binding protein attenuate the proinflammatory response after hemorrhage. Crit Care Med 2005; 33: 391-398.
136. Zhou M, Simms HH, Wang P. Adrenomedullin and adrenomedullin binding protein-1 attenuate vascular endothelial cell apoptosis in sepsis. Ann Surg 2004; 240: 321-330.
137. Ono Y, Okano I, Kojima M, et al. Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis. Biochem Biophys Res Commun 2000; 271: 197-202.
138. Koo DJ, Yoe P, Cioffi WG, et al. Mechanism of the beneficial effects of pentoxifylline during sepsis: maintenance of adrenomedullin responsiveness and downregulation of proinflammatory cytokines. J Surg Res 2000; 91: 70-76.
139. Koo DJ, Zhou M, Chaudry IH, et al. The role of adrenomedullin in producing differential hemodynamic, responses during sepsis. J Surg Res 2001; 95: 207-218.
140. Wang P, Yoo P, Zhou M, et al. Reduction in vascular responsiveness to adrenomedullin during sepsis. J Surg Res 1999; 85: 59-65.
141. Pio R, Elsasser TH, Martinez A, et al. Identification, characterization, and physiological actions of factor H as an adrenomedullin binding protein present in human plasma. Microsc Res Tech 2002; 57: 23-27.
142. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J iel Chem 2001; 276: 12292-12300.
143. Zhou M, Ba ZF, Chaudry IH, et al. Adrenomedullin binding protein-1 modulates vascular responsiveness to adrenomedullin in late sepsis. Am J Physiol Regul Integr Comp, Physiol 2002; 283: R553-R560.
144. Cui Y, Ji Y, Wu R, et al. Adrenomedullin binding protein-1 is downregulated during polymicrobial sepsis in the rat. Int J Mol Med 2006; 17: 925-929.
145. Wu R, Cui X, Dong W, et al. Mechanisms responsible for vascular hyporesponsiveness to adrenomedullin after hemorrhage: the central role of adrenomedullin binding protein-1. Ann Surg 2005; 242: 115-123.
146. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84: 903-934.
147. Nakamura M, Yoshida H, Hiramori K. Comparison of vasodilator potency of adrenomedulling and proadrenomedullin N-terminal 20 peptide in human. Life Sci 1999; 65: 2151-2156.
148. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001; 22: 1693-1711.
149. Hinson JP, Hagi-Pavli E, Thomson LM, et al. Proadrenomedullin N-terminal 20-peptide (PAMP) receptors and signal transduction. in the rat adrenal gland. Life Sci 1998; 62: 439-443.
150. Iwasaki H, Hirata Y, Iwashina M, et al. Specific binding sites for proadrenomedullin N-terminal 20 peptide (PAMP) in the rat. Endocrinology 1996; 137: 3045-3050.
151. Li J, Ren Y, Deng X, et al. Roles of different peptide fragments derived from proadrenomedullin in the regulation of vascular tone in isolated rat aorta. Peptides 2003; 24: 563-568.